Le Lézard
Classified in: Health
Subjects: WOM, RCL, PSF, CFG

Advisory - Duchesnay Inc. recalls certain lots of PregVit and PregVit folic 5 prenatal and postpartum vitamin-mineral supplements because of a packaging error


OTTAWA, Nov. 15, 2019 /CNW/ - Health Canada is advising Canadians that Duchesnay Inc. is recalling certain lots of PregVit vitamin-mineral supplements (for prenatal and postpartum use) and PregVit folic 5 vitamin-mineral supplements (for prenatal use) because blister packages may contain all pink (morning) tablets instead of the correct combination of pink and blue (evening) tablets. The company estimates the issue affects a very small number of products in certain lots (see the table below) and not all products.

PregVit ? box (CNW Group/Health Canada)

There are no quality, safety or effectiveness concerns with the tablets themselves but there is the potential that patients may not take the proper combination of pink and blue tablets if they have received products impacted by the packaging error.

The pink and the blue tablets do not contain the same active ingredients. Women taking all pink tablets will not receive the intended vitamin and mineral supplements. In particular, the pink tablets do not contain folic acid, which is important for the healthy growth of an unborn baby and helps to reduce some types of birth defects called neural tube defects.

Properly packaged products should contain two blister packs, with each blister pack containing 15 pink tablets and 15 blue tablets. The company received a complaint of a product containing a blister pack that contained all pink tablets and no blue tablets.

Who is affected
Women who have bought or are using the affected products.

Affected products

 

Product

DIN

Lot

Expiry

PregVit 

Format 60

02451573

19003

2021-10-31

19001V

2021-09-30

18015V

2021-08-31

18010V

2021-05-31

18012V

2021-04-30

18006V

2020-08-31

18003V

2020-06-30

17019V

2020-05-31

17016

2020-07-31

17002

2020-03-31

16065

2020-02-29

16064

2020-01-31

16045

2019-12-31

16042

2019-12-31

PregVit folic 5 

Format 60

02451581

18022

2021-07-31

18007

2020-10-31

18002

2020-09-30

16053

2019-12-31

 

What consumers should do

Additional information for pharmacists

What Health Canada is doing
Health Canada is monitoring the recall and verifying that the company has effectively addressed the packaging issue. Should additional safety concerns be identified, Health Canada will take appropriate action and inform Canadians as necessary.

Également disponible en français

PregVit ? properly packaged blister pack (CNW Group/Health Canada)

PregVit folic 5 ? box (CNW Group/Health Canada)

PregVit folic 5 ? properly packaged blister pack (CNW Group/Health Canada)

SOURCE Health Canada


These press releases may also interest you

at 06:00
Ceribell, Inc announced the launch of Clarity, a new 24/7 bedside EEG monitoring and alerting technology, at the American Epileptology Society Annual Meeting.  Ceribell's Rapid Response EEG system made bedside EEG possible for critically ill patients...

at 06:00
Intelligent.com, a trusted resource for online degree rankings and higher education planning, has announced the Top 25 Doctorate in Psychology Degree Programs for 2020. The comprehensive research guide is based on an assessment of 148 accredited...

at 03:00
On one end of the humility spectrum, there's the braggers. It doesn't matter if all they've done is fry an egg without burning it - the entire world must know of their accomplishments. Next, there's the humble-braggers. They think they're being...

at 02:40
Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, announced today that it has entered a definitive agreement to acquire all rights to the investigational compound bermekimab from XBiotech Inc. Bermekimab is an...

6 déc 2019
BrainCo's prosthetic hand won Time Magazine's Top 100 Inventions of the Year. The prosthetic hand represents an advancement in assistive technology, providing amputees with an intuitively controlled prosthetic at a lower cost. ...

6 déc 2019
Helix BioPharma Corp. ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the voting results of the Company's annual and special meeting of...



News published on 15 november 2019 at 20:49 and distributed by: